EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma

Stefan G van Ravensteijn iD, Avital L Amir, Daniele V F Tauriello, Carla M L van Herpen, Marye J Boers-Sonderen, Yvonne J W Wesseling, Anne G C van Brussel, Diederick M Keizer, Henk M W Verheul, Kalijn F Bol

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxae108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Stefan G van Ravensteijn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Melanoma, Transforming Growth Factor beta, Immune Checkpoint Inhibitors, Signal Transduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibition (ICI) is highly effective for the treatment of melanoma, but intrinsic resistance is present in a subgroup of patients. TGF-β pathway activity may play a role in this resistance by preventing T-cells from entering the tumor microenvironment, causing immune escape. We investigated the association of TGF-β signal transduction pathway activity with resistance to ICI treatment in advanced melanoma. Furthermore, other pathway activities were analyzed to better understand their potential role in ICI resistance.

Method

The activity of 8 signaling pathways (TGF-β, Hedgehog, MAPK, AR, NOTCH, PI3K, JAK/STAT1-2, and NFkB) was analyzed from tumor tissue from patients with advanced melanoma. Pathway activity scores (PAS) were explored for associations with survival and response to ICI in 34 patients (19 non-responders and 15 responders). A second, independent method to investigate the predictive value of TGF-β pathway activation was conducted by determining levels of phosphorylated SMAD2.

Results

The mean TGF-β PAS of responders vs non-responders was 53.9 vs 56.8 (P = 0.265). No significant relation with progression-free survival was detected for TGF-β activity (P = 0.078). No association between pSMAD2 staining and treatment response or survival was identified. In contrast, Hedgehog scores of responders versus non-responders were 35.7 vs 41.6 (P = 0.038). High Hedgehog PAS was the sole significant predictor of resistance to ICI (OR 0.88, P = 0.033) and worse progression-free survival (HR 1–1.1, P = 0.012).

Conclusion

TGF-β pathway activation showed no significant relation with treatment response to ICI or survival in patients with advanced melanoma. Hedgehog PAS was identified as a possible biomarker associated with both treatment response and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaTransforming Growth Factor betaImmune Checkpoint InhibitorsSignal TransductionSkin NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultSmad2 ProteinDrug Resistance, NeoplasmTumor MicroenvironmentNeoplasm MetastasisAged, 80 and over

Stichwörter der Autor:innen

TGF-betabiomarkerimmunotherapymelanoma

Substanzen

Transforming Growth Factor betaImmune Checkpoint InhibitorsSmad2 ProteinSMAD2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • InnoSIGN B.V. High Tech Campus 11, Eindhoven, the Netherlands.

ORCID-Profile: Stefan G van Ravensteijn

Zitieren

APA

van Ravensteijn, S. G., Amir, A. L., Tauriello, D. V. F., van Herpen, C. M. L., Boers-Sonderen, M. J., Wesseling, Y. J. W., van Brussel, A. G. C., Keizer, D. M., Verheul, H. M. W., & Bol, K. F. (2025). Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae108

Vancouver

van Ravensteijn SG, Amir AL, Tauriello DVF, van Herpen CML, Boers-Sonderen MJ, Wesseling YJW, et al. Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae108

BibTeX
@article{vanRavensteijn2025,
  author = {van Ravensteijn, Stefan G and Amir, Avital L and Tauriello, Daniele V F and van Herpen, Carla M L and Boers-Sonderen, Marye J and Wesseling, Yvonne J W and van Brussel, Anne G C and Keizer, Diederick M and Verheul, Henk M W and Bol, Kalijn F},
  title = {Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxae108}
}
Kostenlos starten →